0001209191-23-044892.txt : 20230807
0001209191-23-044892.hdr.sgml : 20230807
20230807205054
ACCESSION NUMBER: 0001209191-23-044892
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230803
FILED AS OF DATE: 20230807
DATE AS OF CHANGE: 20230807
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hull Hans
CENTRAL INDEX KEY: 0001614876
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39303
FILM NUMBER: 231149043
MAIL ADDRESS:
STREET 1: C/O AVALANCHE BIOTECHNOLOGIES, INC.
STREET 2: 1035 O'BRIEN DRIVE, SUITE A
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PLIANT THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001746473
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474272481
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-481-6770
MAIL ADDRESS:
STREET 1: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-03
0
0001746473
PLIANT THERAPEUTICS, INC.
PLRX
0001614876
Hull Hans
C/O PLIANT THERAPEUTICS, INC.
260 LITTLEFIELD AVENUE
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Business Officer
1
Common Stock
2023-08-03
4
S
0
13069
20.00
D
206114
D
Common Stock
2023-08-03
4
M
0
1800
2.08
A
207914
D
Common Stock
2023-08-03
4
S
0
1800
20.00
A
206114
D
Common Stock
2023-08-04
4
M
0
8791
2.08
A
214905
D
Common Stock
2023-08-04
4
S
0
20050
20.01
D
194855
D
Common Stock
3821
I
See footnote
Common Stock
13985
I
See footnote
Common Stock
13985
I
See footnote
Common Stock (Right to Buy)
2.08
2023-08-03
4
M
0
1800
0.00
D
2028-03-31
Common Stock
1800
40158
D
Common Stock (Right to Buy)
2.08
2023-08-04
4
M
0
8791
0.00
D
2028-03-31
Common Stock
8791
31367
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 3, 2023.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
The shares are held by The Sloger Hull Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.
The shares are held by a trust for the Reporting Person's minor child ("Child A Trust"). The Reporting Person and his spouse serve as trustees for Child A Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The shares are held by a trust for the Reporting Person's minor child ("Child B Trust"). The Reporting Person and his spouse serve as trustees for Child B Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
On January 24, 2019, the Reporting Person was granted stock options, the vesting of which was subject to the achievement of pre-established performance criteria which were achieved, and all of which were subject to the Reporting Person's continuous service to the Issuer.
/s/ Mike Ouimette, attorney-in-fact
2023-08-07